Ruixiao Wang

Papers

Total Citations

H-Index

About

Dr. Ruixiao Wang is a leading urological researcher whose work centers on the evolving management of benign prostatic hyperplasia (BPH) and its associated lower urinary tract symptoms (LUTS). Dr. Wang’s major contribution lies in advancing integrated treatment paradigms that bridge pharmacological therapies, minimally invasive surgical therapies (MISTs), and emerging procedural innovations, offering patients safer, more effective alternatives to traditional invasive surgery. Their highly cited 2025 paper, "Integrated management strategies for benign prostatic hyperplasia," has already garnered 3 citations, reflecting its immediate impact in reshaping clinical decision-making for aging men. Dr. Wang’s research is notable for synthesizing complex treatment algorithms into actionable, patient-centered frameworks, directly improving quality of life outcomes. By championing the shift from aggressive surgical intervention to tailored, stepwise approaches, Dr. Wang has positioned themselves as a key voice in modern urology. Their work continues to influence both clinical practice and future research directions, making them an essential figure for students and clinicians seeking to understand the future of BPH care.